KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Current Assets (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Current Assets for 16 consecutive years, with $825.2 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 23.97% to $825.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $825.2 million through Dec 2025, down 23.97% year-over-year, with the annual reading at $825.2 million for FY2025, 23.97% down from the prior year.
  • Current Assets for Q4 2025 was $825.2 million at Halozyme Therapeutics, down from $1.3 billion in the prior quarter.
  • The five-year high for Current Assets was $1.3 billion in Q3 2025, with the low at $541.9 million in Q2 2022.
  • Average Current Assets over 5 years is $921.3 million, with a median of $934.0 million recorded in 2021.
  • The sharpest move saw Current Assets soared 103.91% in 2021, then plummeted 45.79% in 2022.
  • Over 5 years, Current Assets stood at $926.3 million in 2021, then decreased by 20.22% to $739.0 million in 2022, then increased by 1.0% to $746.4 million in 2023, then soared by 45.41% to $1.1 billion in 2024, then fell by 23.97% to $825.2 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $825.2 million, $1.3 billion, and $1.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.